Top of the morning to you, and a fine one it is. Crystal clear blue skies and a nippy breeze are enveloping the Pharmalot campus this morning, where the official mascot eagerly awaits the start of yet another play date and we are brewing needed cups of stimulation. Our choice today is peppermint mocha. Yum. We are, however, otherwise busy foraging for fascinating and juicy developments. So please keep us in mind when news crosses your own path. But we would be remiss if we did not remind you that a STAT Summit gets under way today with a cast of interesting folks. Meanwhile, here are a few items to get you going. …
Al Sandrock, the top scientist at Biogen (BIIB) and the face of its years-long campaign to develop a treatment for Alzheimer’s disease, is leaving the company after more than two decades, STAT reports. The surprise departure leaves a void in the upper ranks and comes as Biogen faces a worsening business outlook. The company is saddled with a string of setbacks to its research pipeline and is being forced to defend its scientific integrity after the approval of the polarizing Alzheimer’s treatment Aduhelm. Priya Singhal, Biogen’s senior vice president of global safety and regulatory sciences, will replace him on an interim basis. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What’s included? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. This name will appear with your comment
https://www.statnews.com/pharmalot/2021/11/16/covid19-pfizer-biogen-alzheimers-opioids/
